Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study

BACKGROUND: Vaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This phase III study evaluated the safety and efficacy of vaniprevir in combination with peginterferon alfa-2b and ribavirin (PR) for 24 weeks compared with PR alone for 48 weeks in...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Gastroenterol
मुख्य लेखकों: Hayashi, Norio, Nakamuta, Makoto, Takehara, Tetsuo, Kumada, Hiromitsu, Takase, Akiko, Howe, Anita Yee Mei, Ludmerer, Steven W., Mobashery, Niloufar
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer Japan 2015
विषय:
Original Article—Liver, Pancreas, and Biliary Tract
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4805724/
https://ncbi.nlm.nih.gov/pubmed/26403160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-015-1120-x
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन